Skip to content
DataLookout
Menu

ANGEL-BAONCT06101667

Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 18 words Show 5 more changesShow less
    • Sponsor refiled this as active, not recruiting (was completed)
    • Primary completion date: Feb 25, 2026 to Mar 17, 2026
    • Study completion date: Jul 1, 2026 to Dec 31, 2026
    • Secondary endpoints: details revised at 2 of 6 entries
    • Publications: details revised at 1 of 1 entry
  2. Minor Trial completed
    • Primary completion moved earlier from Dec 31, 2026 to Feb 25, 2026
    • Study completion moved earlier from Dec 31, 2027 to Jul 1, 2026
    • Site details revised
    v5
  3. Notable Primary completion date: Sep 2025 to Dec 31, 2026
    • Start date: Oct 15, 2023 to Nov 16, 2023
    • Study completion date: Dec 2025 to Dec 31, 2027
    v4
  4. Notable Eligibility criteria expanded, about 10 words
    • Secondary endpoints revised (6)
    v3
  5. Notable Eligibility criteria expanded, about 10 wordsv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of modified Rankin scale 0-3 at 90 (±14) days after randomization
Timeframe: 90±14 days after randomization

Secondary (6)

MRS score as an ordinal scale at 90 (±14) days after randomization
Rate of mRS 0-2 at 90 (±14) days after randomization
National Institutes of Health Stroke Scale (NIHSS) score at 24 hours after randomization
NIHSS score at 7 days after randomization or discharge (whichever came first)
Functional health status and quality of life (EuroQol Five Dimensions) at 90 (±14) days after randomization
Show 1 moreShow less
Proportion of basilar artery recanalization at 18-36 hours after randomization (confirmed by CTA or MRA)

Arms and interventions

Best medical managementActive comparator

Patients randomly assigned to the control group should receive the best medical management according to the guidelines.

Endovascular treatmentExperimental

Stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intra-arterial thrombolysis (Recombinant tissue plasminogen activator (rt-PA) or urokinase), or the various combinations of these approaches.

Drugs: Best medical management

Procedures: Endovascular treatment

Sites

1 site in 1 country

  • Beijing Tiantan HospitalBeijing, Beijing Municipality, China